Ipratropium bromide


Full Generic Medicine Info
Dosage/Direction for Use

Nasal
Rhinorrhoea associated with rhinitis
Adult: As metered-dose nasal spray: 42 mcg into each nostril 2-3 times daily, up to 84 mcg into each nostril 3-4 times daily for up to 4 days when rhinorrhoea is associated w/ common cold or up to 3 wk when associated w/ seasonal allergic rhinitis.
Child: As metered-dose nasal spray: ≥12 yr 42 mcg into each nostril 2-3 times daily.

Inhalation
Chronic obstructive pulmonary disease
Adult: As metered-dose aerosol: 20-40 mcg 3-4 times daily; single doses of up to 80 mcg may be required in some patients. As soln for nebulisation: 250-500 mcg 3-4 times daily.
Child: As metered-dose aerosol: <6 yr 20 mcg tid; 6-12 yr 20-40 mcg tid. As soln for nebulisation: <6 yr For acute asthma: 125-250 mcg, given no more often than 6 hrly up to a total dose of 1 mg. 6-12 yr For acute and chronic asthma: 250 mcg, repeated as necessary up to a total dose of 1 mg.

Inhalation
Asthma
Adult: As metered-dose aerosol: 20-40 mcg 3-4 times daily; single doses of up to 80 mcg may be required in some patients. As soln for nebulisation: 250-500 mcg 3-4 times daily.
Child: As metered-dose aerosol: <6 yr 20 mcg tid; 6-12 yr 20-40 mcg tid. As soln for nebulisation: <6 yr For acute asthma: 125-250 mcg, given no more often than 6 hrly up to a total dose of 1 mg. 6-12 yr For acute and chronic asthma: 250 mcg, repeated as necessary up to a total dose of 1 mg.
Contraindications
Hypersensitivity to ipratropium, atropine, or its derivatives.
Special Precautions
Patient w/ prostatic hyperplasia/bladder neck obstruction, myasthenia gravis, narrow-angle glaucoma, cystic fibrosis. Pregnancy and lactation. Patient Counselling This drug may cause dizziness, accommodation disorder, mydriasis and blurred vision, if affected, do not drive or operate machinery.
Adverse Reactions
Dry mouth, constipation, tachycardia, palpitations, arrhythmias, nausea and vomiting, dyspepsia, headaches, dizziness, ocular complications (e.g. mydriasis, narrow-angle glaucoma). Rarely, urinary retention, hypersensitivity reactions (e.g. urticaria, angioedema, rash); nasal dryness, irritation and epistaxis.
Potentially Fatal: Paradoxical bronchospasm, anaphylaxis.
Drug Interactions
Additive bronchodilatory effect w/ β-adrenergic drugs and xanthine preparations.
Action
Ipratropium bromide causes bronchodilation by blocking the action of acetylcholine at parasympathetic site in bronchial smooth muscle. It also inhibits serous and seromucous gland secretions by nasal application.
Onset: Bronchodilation: W/in 15 min.
Duration: 2-5 hr (oral inhalation).
Absorption: 10-30% of a dose is deposited in the lungs while only a small amount reaches systemic circulation. Poorly absorbed from the GI tract. Bioavailability: 2% (oral inhalation); 7-28% (nasal).
Distribution: Plasma protein binding: ≤9% (oral inhalation); <20% (nasal).
Metabolism: Metabolised via ester hydrolysis (41%) and conjugation (36%).
Excretion: Via urine and faeces. Elimination half-life: 2 hr (oral inhalation); 1.6 hr (nasal).
Storage
Inhalation: Aerosol/nasal spray: Store at 25°C. Protect from light or heat. Soln for nebulisation: Store between 15-30°C. Protect from light. Nasal: Aerosol/nasal spray: Store at 25°C. Protect from light or heat. Soln for nebulisation: Store between 15-30°C. Protect from light.
CIMS Class
Antiasthmatic & COPD Preparations / Nasal Decongestants & Other Nasal Preparations
ATC Classification
R01AX03 - ipratropium bromide ; Belongs to the class of other nasal preparations for topical use.
R03BB01 - ipratropium bromide ; Belongs to the class of other inhalants used in the treatment of obstructive airway diseases, anticholinergics.
Disclaimer: This information is independently developed by CIMS based on ipratropium bromide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in